ArticleDiabetes care2026
Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice.
Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveGlycated hemoglobin (HbA1c) and average glucose (AG) can show discordance due to personal variations in red blood cell (RBC) physiology, creating management difficulties. Our aims were to understand the size of the problem and refine this glycemic metric by adjusting for personal differences in RBC characteristics. RESEARCH AND DESIGN AND
methodsA 26-week prospective study was conducted in individuals with type 1 diabetes (T1D) or type 2 diabetes across four racial groups with HbA1c collected every 2 weeks and continuous glucose monitoring (CGM) used throughout. Personal glycation ratio (PGR) was derived from HbA1c and AG data (weeks 0-12), allowing calculation of personalized HbA1c (pA1C) and subsequent testing (weeks 20-26). The relationship between AG and HbA1c or pA1C was then analyzed, documenting a clinically meaningful discordance of ≥0.5%. In addition, we used real-world data sets to further validate the accuracy of pA1C at reflecting glucose exposure.
resultsOf 257 participants (19% T1D) with complete CGM and HbA1c data sets, mean age (±SD) was 53 ± 14 years (45% females). The racial background was 35% Asian, 30% White, 22% Black, and 14% other/mixed. Of the total study population, 33% showed ≥0.5% HbA1c-AG discordance, with the Black population affected most (41% discordance). Use of pA1C reduced the discordance in the whole population to 14% (58% reduction), while this was reduced in the Black population to 12% (71% reduction).
conclusionsHbA1c-AG discordance is common, particularly in the Black population, with pA1C improving alignment with glucose levels, potentially helping to optimize clinical management and reduce health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.